A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
Public ClinicalTrials.gov record NCT00051051. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with metastatic breast cancer. Patients with histologically confirmed metastatic (Stage IV) breast cancer and who have received no more than 2 prior cytotoxic chemotherapy regimens are eligible for this study. CI-1033 is administered orally. Patients are required to have blood tests periodically while receiving treatment and will be closely monitored throughout the study for possible side effects and response to treatment. Patients may not have received any prior treatment with other agents that target erbB receptors, including Herceptin (trastuzumab) or Iressa (gefitinib).
Study identification
- NCT ID
- NCT00051051
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2002 (Type not available)
- Primary completion
- Not listed
- Completion
- May 2005 (Actual)
- Last update posted
- May 4, 2007
2002 – 2005
United States locations
- U.S. sites
- 42
- U.S. states
- 16
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Montgomery | Alabama | 36106 | — |
| Pfizer Investigational Site | Arroyo Grande | California | 93420 | — |
| Pfizer Investigational Site | Montebello | California | 90640 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80010 | — |
| Pfizer Investigational Site | Aventura | Florida | 33180 | — |
| Pfizer Investigational Site | Miami Beach | Florida | 33140 | — |
| Pfizer Investigational Site | Plantation | Florida | 33324 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60637-1470 | — |
| Pfizer Investigational Site | Maywood | Illinois | 60153 | — |
| Pfizer Investigational Site | Kansas City | Kansas | 66112 | — |
| Pfizer Investigational Site | Lenexa | Kansas | 66214 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66210 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02115 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109-0922 | — |
| Pfizer Investigational Site | Brownstown | Michigan | 48183 | — |
| Pfizer Investigational Site | Dearborn | Michigan | 48126 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | West Bloomfield | Michigan | 48322 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64111 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64131 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64154 | — |
| Pfizer Investigational Site | Lee's Summit | Missouri | 64064 | — |
| Pfizer Investigational Site | The Bronx | New York | 10461 | — |
| Pfizer Investigational Site | The Bronx | New York | 10467 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Pfizer Investigational Site | Gallatin | Tennessee | 37066 | — |
| Pfizer Investigational Site | Hermitage | Tennessee | 37076 | — |
| Pfizer Investigational Site | Lebanon | Tennessee | 37087 | — |
| Pfizer Investigational Site | Murfreesboro | Tennessee | 37130 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37207 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37211 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84112 | — |
| Pfizer Investigational Site | Walla Walla | Washington | 99362 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00051051, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2007 · Synced Oct 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00051051 live on ClinicalTrials.gov.